Stephens & Co. Maintains Overweight on Kymera Therapeutics, Raises Price Target to $110

Benzinga · 2d ago
Stephens & Co. analyst Sudan Loganathan maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $65 to $110.